Data Integration and Analysis Tools: Accessible Resources for Integration and Analysis of Carbohydrate and Glycoconjugate Data in the Context of Comparable Gene, Protein, and Lipid Data (U01)

RFA-RM-16-021
Data Integration and Analysis Tools: Accessible Resources for Integration and Analysis of Carbohydrate and Glycoconjugate Data in the Context of Comparable Gene, Protein, and Lipid Data (U01)
Department of Health and Human Services
National Institutes of Health

successful-grant-writing-strategies-for-an-r-award-15-638

Research Objectives and Scope

The analysis and integration of carbohydrate and glycoconjugate data is a complex challenge. Present computational and informatics technologies for carbohydrate analysis are decades behind those developed for nucleic acids and proteins. Like other aspects of glycobiology, progress in glycoinformatics is sporadic and fragmented. The resulting tools are primitive, and poorly integrated, and adoption by non-specialists has been slow. Certain glycoinformatics tools, such as glycan structure databases, have been developed. These databases, however, are limited and balkanized, and are not matched with tools for interrogating the databases in meaningful ways. They are also not well-integrated with databases for proteins or genomic information. Other classes of glycoinformatics tools are in their infancy, or entirely lacking. Examples include algorithms for spectral interpretation to support glycoconjugate structure determination, or interpretation of glycan array binding data.

Recent community-led efforts to arrive at standardization of glycan nomenclature as expressed in databases, interoperability of databases, and reporting of experimental metadata have been promising. Two important features of these recent efforts are: (1) they have been inclusive, community-driven projects, and (2) they have focused on preserving the utility of the tools already created.  Efforts to bring glycoinformatics up to the current state of the art available for the other classes of biological macromolecules must be grounded in a clearly articulated vision for addressing the significant challenges confronting the field, and facilitate participation of many independent research groups. The project should create an environment that enables current and future software developers to join this effort with a clear understanding of the framework within which their contributions will be most effective.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-RM-16-021
Funding Opportunity Title: Data Integration and Analysis Tools: Accessible Resources for Integration and Analysis of Carbohydrate and Glycoconjugate Data in the Context of Comparable Gene, Protein, and Lipid Data (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:  
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:  
Expected Number of Awards: 1
CFDA Number(s): 93.310 — Trans-NIH Research Support
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Sep 16, 2016
Last Updated Date: Sep 16, 2016
Original Closing Date for Applications: Nov 28, 2016  
Current Closing Date for Applications: Nov 28, 2016  
Archive Date: Dec 29, 2016
Estimated Total Program Funding: $2,000,000
Award Ceiling: $1,500,000
Award Floor:

Eligibility

Eligible Applicants: City or township governments
Special district governments
Public housing authorities/Indian housing authorities
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
State governments
Independent school districts
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
County governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The Common Fund Program – Accelerating Translation of Glycoscience: Integration and Accessibility – aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-16-021.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

BRAIN Initiative: Development and Validation of Novel Tools to Analyze Cell-Specific and Circuit-Specific Processes in the Brain (R01)

RFA-MH-17-220
BRAIN Initiative: Development and Validation of Novel Tools to Analyze Cell-Specific and Circuit-Specific Processes in the Brain (R01)
Department of Health and Human Services
National Institutes of Health

neuron

Research Objectives

This funding opportunity announcement (FOA) is designed to support development and validation of novel tools to facilitate the detailed analysis of cells and circuits and provide insights into the neural circuitry and structure underlying complex behaviors. The human brain consists of an estimated one hundred billion neurons and more than one trillion supporting glial cells that are uniquely organized to confer the extraordinary computational activities of the brain. Cell types are categorized by their anatomical position, neurotransmitter content, dendritic and axonal connections, receptor profile, gene expression profile and distinct electrical properties. Although the human brain has long been the focus of numerous studies with many major achievements along the way, to date we remain largely ignorant about the specific details such as cell types and connections that are responsible for rapid information processing. Defining cellular and circuit-level function is dependent on detailed knowledge about the components and structure of the circuit. Such knowledge, in turn, is fundamental to understanding how these features underlie cognition and behavior, which should aid in the development of targeted cell-type and circuit-specific therapeutics to treat brain disorders. This initiative is focused on developing tools (or vastly improving existing tools) to enable access to individual cells and defined groups of cells within neuronal circuits. The tools sought through this FOA can include novel genetic or non-genetic methods for targeted delivery of genes, proteins, and chemicals to specific cells or tightly defined cell types and circuits.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-MH-17-220
Funding Opportunity Title: BRAIN Initiative: Development and Validation of Novel Tools to Analyze Cell-Specific and Circuit-Specific Processes in the Brain (R01)
Opportunity Category: Discretionary
Opportunity Category Explanation:  
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Income Security and Social Services
Category Explanation:  
Expected Number of Awards:  
CFDA Number(s): 93.173 — Research Related to Deafness and Communication Disorders
93.213 — Research and Training in Complementary and Integrative Health
93.242 — Mental Health Research Grants
93.273 — Alcohol Research Programs
93.279 — Drug Abuse and Addiction Research Programs
93.286 — Discovery and Applied Research for Technological Innovations to Improve Human Health
93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
93.865 — Child Health and Human Development Extramural Research
93.866 — Aging Research
93.867 — Vision Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Aug 10, 2016
Last Updated Date: Sep 16, 2016
Original Closing Date for Applications: Nov 02, 2016  
Current Closing Date for Applications: Oct 13, 2017  
Archive Date: Nov 12, 2017
Estimated Total Program Funding:  
Award Ceiling:  
Award Floor:  

Eligibility

Eligible Applicants: Private institutions of higher education
State governments
Special district governments
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
County governments
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Independent school districts
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
City or township governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-220.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

“High” or “Medium” Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)

PA-16-425
“High” or “Medium” Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)
Department of Health and Human

Print Services
National Institutes of Health

Section I. Funding Opportunity Description
Purpose

The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population.

Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information.

This FOA runs in parallel with another FOA of identical scientific scope, PA-16-426, which utilizes the Exploratory/Developmental Grant (R01) mechanism.

Scope

In 2015, NIH and OAR mandated that in the future, AIDS funds can only be used in for research addressing “high” or “medium” priority areas of AIDS research as defined in NOT-OD-15-137“NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding”.

Topics considered “low priority” AIDS in NOT-OD-15-137 are not appropriate for this PAR except basic research in tumors caused by KSHV has, for the moment, been considered as “high priority” AIDS and will be eligible for funding under this PAR.  All applications considered for funding will be reviewed by OAR and must be aligned with the priorities in NOT-OD-15-137.

Specific areas of study in the indicated categories may include, but are not limited to, the following examples:

A) Biomarkers, Diagnostics, and Therapeutics:

  • Discovery of reliable molecular and immunological diagnostic and prognostic biomarkers and pathogen markers, useful for early detection, progression, or response to treatment of non-AIDS-defining and AIDS-defining malignancies;
  • Discovery and development of novel targets and efficacious new therapeutic agents, interventional strategies, or improved delivery systems for the treatment of cancer in people with HIV infection, however clinical trials are not permitted;
  • Studies to understand the pharmacokinetics of targeted therapies for AIDS-defining and non-AIDS defining malignancies in the context of highly active antiretroviral therapy and;
  • Studies utilizing existing cohorts and tissue banks of human specimens from a wide spectrum of AIDS-defining and non-AIDS defining malignancies to develop biomarker, diagnostic assays, or analyze samples and data acquired from these cohorts is encouraged. Examples of such cohorts and repositories include:
  • AIDS and Cancer Specimen Resource (ACSR),
  • Women’s Interagency HIV Study (WIHS)),
  • Veterans Aging Cohort Study (VACS)
  • Multicenter AIDS Cohort Study (MACS).

Investigators are also encouraged to utilize infrastructure support of the Centers for AIDS Research (CFAR) or NCI designated Cancer Centers if located at those institutions.

However, descriptive research and recruitment or retention of cohorts are not appropriate for this FOA.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PA-16-425
Funding Opportunity Title: “High” or “Medium” Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)
Opportunity Category: Discretionary
Opportunity Category Explanation:  
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:  
Expected Number of Awards:  
CFDA Number(s): 93.121 — Oral Diseases and Disorders Research
93.393 — Cancer Cause and Prevention Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Sep 07, 2016
Last Updated Date: Sep 07, 2016
Original Closing Date for Applications: Sep 07, 2019  
Current Closing Date for Applications: Sep 07, 2019  
Archive Date: Oct 08, 2019
Estimated Total Program Funding:  
Award Ceiling: $200,000
Award Floor:

Eligibility

Eligible Applicants: Special district governments
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Public and State controlled institutions of higher education
County governments
Independent school districts
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
State governments
City or township governments
Native American tribal governments (Federally recognized)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PA-16-425.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Federal prize competition seeks innovative ideas to combat antimicrobial resistance

Source: https://www.nih.gov/news-events/news-releases/federal-prize-competition-seeks-innovative-ideas-combat-antimicrobial-resistance

Contestants will vie for $20 million in prizes to develop new innovative laboratory diagnostic tools that detect and distinguish antibiotic resistant bacteria.

A federal prize competition launched today is calling for innovative ideas for rapid, point-of-care laboratory diagnostic tests to combat the development and spread of drug resistant bacteria, a rising public health threat. Antibiotic resistant bacteria cause at least 2 million infections and 23,000 deaths each year in the United States, according to the Centers for Disease Control and Prevention.

The Antimicrobial Resistance Diagnostic Challenge will award $20 million in prizes over all phases of the competition for new, innovative and novel laboratory diagnostic tests. The diagnostic tests being sought are those that identify and characterize antibiotic resistant bacteria and those that distinguish between viral and bacterial infections to reduce unnecessary uses of antibiotics, a major cause of drug resistance. The prize is sponsored by two U.S. Department of Health and Human Services components, the National Institutes of Health and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) in support of the National Action Plan for Combating Antibiotic Resistant Bacteria(link is external).

“The growing incidence of serious infections from antibiotic resistant bacteria presents a critical risk to the public health of our nation,” said NIH Director Francis S. Collins, M.D., Ph.D. “My hope is that this competition will spur exceptional innovators to rise to the challenge and deliver effective tools to help manage this significant problem.”Scanning electron micrograph of neutrophil ingesting methicillin-  resistant Staphylococcus aureus bacteria.

With real-time detection, healthcare providers would be able to identify infecting pathogens and resistance factors within hours, rather than the two to three days or longer that the standard microbiological culture processes require. Such knowledge would allow tailoring of treatments, minimizing the broad-spectrum antibiotic approach used by many clinicians today.

“This effort even goes beyond public health,” said Nicole Lurie, M.D., M.S.P.H., assistant secretary for preparedness and response. “Combating antibiotic-resistant bacteria is a priority issue for economic and national security.”

Concepts must be submitted by Jan. 9, 2017, for the first phase of the competition. Up to 20 semi-finalists will be selected from the applicant pool, each receiving up to $50,000. In the second phase of the competition, on Dec. 3, 2018, up to 10 finalists will be selected to each receive up to $100,000.  These funds can be used to develop prototypes for evaluation by two CLIA(link is external)-certified independent laboratories, which will be considered when final winners are selected. In the final phase, winners are expected to be announced on July 31, 2020.  The competition specifies that up to three winners can be selected, and winners will share an amount equal to or greater than $18 million.

NIH’s National Institute of Allergy and Infectious Diseases and ASPR’s Biomedical Advanced Research and Development Authority (BARDA) each contributed $10 million to the challenge. The CDC and the U.S. Food and Drug Administration provided technical and regulatory expertise to the design of the challenge competition. Technical criteria, objectives and performance characteristics of laboratory diagnostics that would be considered for the prize were informed by stakeholder input from a public workshop and a request for information.  For more information about the challenge or how to apply, please visit the challenge website(link is external).

About the Biomedical Advanced Research and Development Authority (BARDA): BARDA, within the HHS Office of the Assistant Secretary for Preparedness and Response, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. For more information about BARDA, visit www.phe.gov/about/BARDA/Pages/default.aspx(link is external).

About the Office of the Assistant Secretary for Preparedness and Response (ASPR): ASPR leads HHS in preparing the nation to respond to and recover from adverse health effects of emergencies, supporting communities’ ability to withstand adversity, strengthening health and response systems, and enhancing national health security. For more information about ASPR and for expertise, tools, and resources to help your community prepare, respond and recover from public health emergencies, visitwww.phe.gov(link is external).

About the National Institute of Allergy and Infectious Diseases (NIAID): NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Intramural NIGMS Postdoctoral Research Associate (PRAT) Program (Fi2)

PA-16-130
Intramural NIGMS Postdoctoral Research Associate (PRAT) Program (Fi2)
Department of Health and Human Services
National Institutes of Health1-1NIHinnovationNew

Funding Opportunity Description

In 1965, the first cohort of postdoctoral fellows entered the NIGMS PRAT Program to begin a period of research training in the NIH Intramural Research Program.  Since this time, numerous PRAT alumni have become leaders in their respective fields and across multiple career sectors.  Although this program grew out of a desire to train more individuals in the field of pharmacology, the program has broadened over time and now supports all research areas within the mission of NIGMS.  In 2012, the name of the program was changed to the Postdoctoral Research Associate (PRAT) Program in recognition of the diversity of disciplines supported by the program, but the core features of the program remain the same.  The NIGMS PRAT Program continues to provide access to excellent research, mentoring, and career development resources in the NIH Intramural Research Program and maintains a focus on training leaders in the basic biomedical sciences.

The NIGMS PRAT Program’s overarching goal is to provide high-quality research training in the basic biomedical sciences, in NIH intramural research laboratories, to a diverse group of postdoctoral fellows to prepare them for leadership positions in biomedical careers. This training includes a mentored laboratory experience as well as intensive career and leadership development activities.  Fellows selected for the NIGMS PRAT Program will receive three years of support from this mechanism.

The NIGMS PRAT Program will support fellowship training within the NIH Intramural Research Program that is focused on NIGMS mission-related areas of basic biomedical science. These include but are not limited to cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biological chemistry, computational biology, technology development and bioinformatics. Studies employing model organisms are encouraged.  Fellows can conduct this work in any of the NIH Institutes or Centers with an Intramural Research Program, with mentors who have relevant experience in these areas of research.  This arrangement allows fellows from a wide array of diverse scientific disciplines to interact on a regular basis and to exchange ideas.

The NIGMS PRAT program distinguishes itself from other postdoctoral training opportunities on the NIH campus through its approach to cultivating the next generation of leaders in the basic biomedical sciences.  Fellows selected for this program are from a wide array of basic biomedical research disciplines.  The fellows interact on a regular basis to present their research and exchange ideas during a monthly seminar series combining a research presentation from a current PRAT fellow with a presentation from an outside speaker.  This communication across disciplines fosters discussion of new research approaches and a deeper appreciation of the contributions these diverse disciplines make to the basic biomedical research enterprise.  The program further broadens the experience of participating fellows by providing intensive mentoring and defined career development activities focused on topics such as leadership skills, oral presentations, and grant-writing as part of the training curriculum.   Fellows selected for the PRAT program are required to participate in the PRAT-sponsored training activities.  The PRAT Program Director(s) oversees all activities of the NIGMS PRAT Program and provides additional mentoring to PRAT fellows.

NIGMS PRAT fellows are encouraged to broaden their training by attending scientific seminars on the NIH campus, traveling to scientific meetings, participating actively in lab meetings, making scientific presentations and publishing the results of their research. Fellows receive formal training in the ethical conduct of research and scientific methods, including a focus on the reproducibility of data. All fellows are strongly encouraged to take courses in quantitative biology and statistics, if they have not already done so. Fellows are exposed broadly to the cutting-edge technologies for which the intramural program is noted.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PA-16-130
Funding Opportunity Title: Intramural NIGMS Postdoctoral Research Associate (PRAT) Program (Fi2)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.859 — Biomedical Research and Research Training
Cost Sharing or Matching Requirement: No
Posted Date: Mar 11, 2016
Last Updated Date: Mar 11, 2016
Original Closing Date for Applications: Oct 03, 2018  
Current Closing Date for Applications: Oct 03, 2018  
Archive Date: Nov 03, 2018
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
County governments
State governments
Special district governments
City or township governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The NIGMS Postdoctoral Research Associate (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences, in NIH intramural research laboratories, to a diverse group of postdoctoral fellows to prepare them for leadership positions in biomedical careers. The research projects proposed should focus on NIGMS mission-related areas of basic biomedical science. These include cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biological chemistry, computational biology, technology development and bioinformatics. Studies employing model organisms are encouraged.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PA-16-130.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Limited Competition for the Continuation of the Scientific Data Research Center (SDRC) for the NIDDK Gastroparesis Consortium (U24)

RFA-DK-16-507
Limited Competition for the Continuation of the Scientific Data Research Center (SDRC) for the NIDDK Gastroparesis Consortium (U24)
Department of Health and Human Services
National Institutes of Health

Background

Gastroparesis is a chronic symptomatic disorder associated with delayed gastric emptying.

Gastroparesis predominantly affects young women (females outnumber males by a ratio of 4:1, the average age is 34). The symptomatic profile of gastroparesis includes nausea (90% of patients), vomiting (>80%), bloating (75%), early satiety (60%), and abdominal pain (~50%). Symptoms in individual patients can vary in both the combination of symptoms and their severity. Because of its chronic and often intractable nature, the disorder has a tremendous impact on both patients and society. Gastroparesis remains difficult to treat, in large part, because of the lack of knowledge of the underlying pathophysiology. Several factors have impeded the progress in this field including the paucity of patients seen by any one center, the absence of uniform diagnostic criteria, and the lack of generally available and reliable methods for physiological testing. Given the complexity of the problem, and the profound degree of morbidity associated with this disorder, an important need exists to study patients in a systematic manner. Such studies can best be achieved by recruiting patients and collecting data from multiple centers as part of a network of investigators focused on this disorder. In recognition of this fact, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the Gastroparesis Clinical Research Consortium (GpCRC) in 2006 and renewed the consortium in 2010. Since many gaps still existed despite the progress of the consortium, in April 2015, an External Scientific Committee recommended support of the Consortium activities for another 5 years.

Research Objectives
Through the acquisition of a cohort of well-characterized patients and associated biospecimens (blood, stools and when feasible gastric  tissue), the clinical research consortium  will provide the resources and collaborative opportunities necessary for achieving many of the research objectives identified in the strategic plan of NIDDK for Gastroparesis.

The overriding objective of this research program is to pursue clinical research on Gastroparesis  (both sporadic and  associated with diabetes mellitus type 1 and 2 and obesity), by identifying and characterizing a large cohort of patients with gastroparesis to encourage translational research focusing upon elucidating the pathogenesis that will provide the basis for understanding the natural history and developing means of diagnosis, treatment and clinical management of Gastroparesis  and its sequela: chronic abdominal pain, nausea, vomiting, poor metabolic control and impaired quality of life.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-DK-16-507
Funding Opportunity Title: Limited Competition for the Continuation of the Scientific Data Research Center (SDRC) for the NIDDK Gastroparesis Consortium (U24)
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:
Expected Number of Awards: 1
CFDA Number(s): 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research
Cost Sharing or Matching Requirement: No
Posted Date: Dec 22, 2015
Creation Date: Dec 22, 2015
Original Closing Date for Applications: Mar 2, 2016  
Current Closing Date for Applications: Mar 2, 2016  
Archive Date: Apr 2, 2016
Estimated Total Program Funding: $4,300,000
Award Ceiling: $1,000,000
Award Floor:

Eligibility

Eligible Applicants:
Private institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) invites an application for the Scientific Data Research Center (SDRC) of the Gastroparesis Clinical Research Consortium (GpCRC). The purpose of this FOA is to allow additional follow-up of GpCRC participants. The companion FOA, RFA-DK-16-010 will support continuation of the GpCRC Clinical Centers (CC).
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-507.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)

PAR-16-021
NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)
Department of Health and Human Services
National Institutes of Health

fig1

Types of Research Projects

This FOA is intended to support studies of common, complex disorders that significantly affect heart, lung, and blood (HLB) systems. Applicants should contact NHLBI staff prior to preparing an application to discuss the purpose and scope of their applications and to obtain updates regarding the technical requirements and analytical capabilities of the program. Applicants may, in a single application, apply to use one or more of the five omics assays listed above to accomplish a cohesive research goal. In accordance with the NIH Genomic Data Sharing Policy, all omics and related phenotypic data are expected to be shared with the broader research community through a public database such as dbGaP, consistent with achieving the goals of the program. Since dbGaP is built primarily for genotypic data, NIH may work with applicants to determine the details of how other omics datasets should be stored in dbGaP and/or other related databases supported by NIH.  Successful applicants will be invited and expected to join NHLBI’s TOPMed consortium and participate in its advisory and collaborative discussions.

Whole Genome Sequencing (WGS):

In general, WGS applications may aim to discover influential genetic variants underlying HLB disorders using various experimental designs (e.g., family-based, case-control, or a mix of both); if the same subjects for WGS also have other omics data, applicants may use integrative omics approaches to identify gene-regulatory networks or other functions of genomic variants. Currently, this FOA offers a standard protocol for sequencing whole human genome from high quality genomic DNA (preferably not whole genome amplified DNA). An NHLBI-designated informatics center will perform basic data processing, including variant-calling (e.g., SNPs, SNPs, and copy number variants (CNVs)) as well as submission of sequencing data to dbGaP. Applicants may also perform their own variant-calls if the standard variant-call is not appropriate to their research aims. For applicants with limited experience in or resources for handling genomic data, the sequencing centers and/or the NHLBI’s informatics center will be able to provide some genomic data analysis capacity, and those applicants will need to work with the centers to provide clinical measurements and other data required for phenotype-genotype analyses. For applications using large numbers of samples, applicants are encouraged, when possible, to divide sample collections into smaller, phased projects within a single application, starting with the minimum number of subjects needed for initial discovery. After approval to access the sequencing capacity, X01 applicants will work with NHLBI, NHGRI, and the sequencing centers to determine the timing and number of DNA samples to be sequenced.

Other Omics Assays:

Omics data other than whole genome sequence (e.g., RNA, methylation, metabolites, and proteins) may be highly useful for studies of gene-gene and gene-environment interactions. Such studies benefit from the availability of datasets which contain multi-omics data and WGS data that have all been measured on the same subjects and which also include rich clinical and environmental measurements. Because the sample preparation protocols for other omics measures (RNA-seq, DNA methylation, metabolite-profiling, and protein profiling) are expected to be more complex than that for WGS, applicants are encouraged to consult the FAQ page and contact NHLBI staff for updated protocol specifications. Large scale applications are permitted, but applicants proposing large sample sizes are encouraged to organize their study as a series of phased projects involving a smaller number of samples in each phase, if possible.

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-021
Funding Opportunity Title: NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)
Opportunity Category: Discretionary
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards: 10
CFDA Number(s): 93.233 — National Center on Sleep Disorders Research
93.837 — Cardiovascular Diseases Research
93.838 — Lung Diseases Research
93.839 — Blood Diseases and Resources Research
Cost Sharing or Matching Requirement: No
Posted Date: Oct 29, 2015
Creation Date: Oct 30, 2015
Original Closing Date for Applications: Jan 18, 2019  
Current Closing Date for Applications: Jan 18, 2019  
Archive Date: Feb 18, 2019
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
Native American tribal governments (Federally recognized)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
Independent school districts
State governments
Private institutions of higher education
County governments
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Public and State controlled institutions of higher education
City or township governments
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-021.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster